

Brief Summary
See package insert for full prescribing information.
Indications and Usage: Effexor XR is indicated for the treatment of depression and for the treatment of Generalized Arxiety Disorder (GAD).

Brief Summary

See package insert for full prescribing information.
Indications and Usage: Effexor XR is indicated for the treatment of depression and for the treatment of Generalized Analogy Disorder (GAD)

Indications and Usage: Effexor XR is indicated for the treatment of depression and for the treatment of Generalized Analogy Disorder (GAD)


Analogy Disorder (GAD)

Contrained and the state of the stat

heart rate for Etheor XH-freated patients was 4 beats per minute. In short-ferm GAD studies, mean charges in Q1c or Effext XH-reated patients du off offer significants of these charges is cliented for the control of the control of

of backs in degreeate high related names, amonte, du mach, fuzzines, incoming, and commerce in 115, bricks to critical depression trials related hyperteness, during, pareptiness, therein, and commerce morely brained vation, and absormed fromthy debleyed decadation. In 400 miles included hyperbolic states in 116, control of the control

WYETH-AYERST LABORATORIES



Visit us at www.EFFEXORXR.com

Please see brief summary of Prescribing Information on adjacent page.

## The efficacy and safety of EFFEXOR XR for pediatric use have not been established.

EFFEXOR XR is contraindicated in patients taking monoamine oxidase inhibitors (MAOIs). EFFEXOR XR should not be used in combination with an MAOI or within at least 14 days of discontinuing treatment with an MAOI; at least 7 days should be allowed after stopping EFFEXOR XR before starting an MAOI.

The most common adverse events reported in EFFEXOR XR placebo-controlled depression trials (incidence ≥10% and ≥2× that of placebo) were nausea, dizziness, somnolence.

Reference: 1. Data on file, Wyeth-Averst Laboratories, Philadelphia, Pa.

abnormal ejaculation, sweating, dry mouth, and nervousness; and in GAD trials were nausea, dry mouth, insomnia, abnormal ejaculation, anorexia, constipation, nervousness, and sweating.

Treatment with venlafaxine is associated with sustained increases in blood pressure (BP) in some patients. Three percent of EFFEXOR XR patients in depression studies (doses of 75 to 375 mg/day) and 0.4% in GAD studies (doses of 75 to 225 mg/day) had sustained BP elevations. Less than 1% discontinued treatment because of elevated BP. Regular BP monitoring is recommended.